Eli Lilly and Company reported a 54% increase in revenue for Q3 2025, reaching $17.60 billion, fueled by strong sales of Mounjaro and Zepbound. The pharmaceutical giant has raised its full-year revenue forecast to between $63.0 billion and $63.5 billion, with earnings per share (EPS) now expected to be between $21.80 and $22.50. Non-GAAP EPS for the quarter was $7.02, surpassing market expectations. The company also announced significant advancements in its research and development pipeline, including securing FDA and EU approvals for new treatments, underscoring its commitment to innovation and growth in the pharmaceutical sector.